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Amelioration of diabetic nephropathy by treatment with monoclonal
antibodies against glycated albumin. The pathogenesis of diabetic ne-
phropathy is incompletely understood, but increased nonenzymatic
glycation of proteins is considered an important contributory factor.
Glycated albumin, which is increased in diabetic sera and is preferen-
tially transported into the renal glomerulus, induces an increase in Type
IV collagen production and a decrease in proliferative capacity by
mesangial cells in culture. These effects resemble the abnormalities that
characterize the glomerular mesangium in diabetes and are prevented
by monoclonal antibodies that specifically react with Amadori adducts
in glycated albumin. To explore the possibility that the in vitro effects of
glycated albumin on mesangial cell biology pertain to the in vivo
situation, we examined the effect of treatment with the A717 monoclo-
nal antibodies on glomerular functional and structural changes in a
rodent model of genetic diabetes, the db/db mouse. Weekly parenteral
antibody administration reduced the elevated albumin excretion and
attenuated the mesangial expansion that were observed in the untreated
db/db mice that served as controls. Monoclonal antibody treatment also
was shown to lower plasma concentrations of glycated albumin in
diabetic mice. Thus, reducing glycated albumin concentrations and/or
blocking its biologically active epitopes has a salutary influence on the
pathogenesis of diabetic nephropathy. The findings indicate that gly-
cated albumin participates in the development of the glomerular lesion
in the db/db mouse, and suggest a new approach to the therapy of this
complication of diabetes.
Diabetic nephropathy is the single largest cause of end-stage
renal disease in the United States, and develops in 30 to 50% of
patients with insulin dependent diabetes and in many with
non-insulin dependent diabetes [1—5]. The dramatic results of
the Diabetes Control and Complications Trial (DCCT) have
established that hyperglycemia contributes to this and other
complications of diabetes [6], but the mechanisms by which it
does so remain incompletely elucidated. Among current theo-
ries seeking to define mechanistic links between hyperglycemia
and the pathogenesis of diabetic complications, the biologic
consequences arising from excess nonenzymatic glycation of
proteins in diabetes figure prominently.
Nonenzymatic glycation is a condensation reaction between
free glucose and reactive protein amino groups that gives rise to
stable Amadori adducts in glycated proteins [7—9]. Although
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subsequent rearrangements may lead to the formation of incom-
pletely defined advanced glycation end (AGE) products, the
Amadori adduct is the predominant form in which circulating
glycated proteins exist in vivo and its concentration is signifi-
cantly increased in diabetes with attendant hyperglycemia
[10—15]. Notably, the glomerular mesangium in diabetes is
bathed with serum containing increased concentrations of gly-
cated proteins, which are preferentially transported across the
glomerular filtration barrier [16], and there is increasing evi-
dence that glycated serum proteins adversely influence glomer-
ular physiology and biochemistry. For example, the enhanced
uptake of glycated albumin by glomerular mesangial and epi-
thelial cells is accompanied by increased hydrogen peroxide
production [17]. Injection of nondiabetic mice with glycated
plasma proteins can induce pseudodiabetic glomerular lesions
[18]. Normal rats transfused with glycated serum proteins
containing Amadori products of the glycation reaction in con-
centrations similar to those found in streptozotocin-diabetic
rats manifest hyperfiltration, an early functional abnormality
implicated in the development diabetic nephropathy [19]. We
have shown that human serum containing concentrations of
glycated albumin found in diabetic subjects stimulates Type IV
collagen synthesis and gene expression and inhibits prolifera-
tion by mesangial cells in culture [20]. Supplementation of
media with purified glycated albumin also induces an increase in
Type IV collagen production and a decrease in proliferative
capacity by mesangial cells in culture [21]. This constellation of
changes resembles the abnormalities such as mesangial matrix
expansion in association with decreased cellularity that charac-
terize the diabetic renal glomerulus [22—26]. We therefore
reasoned that, if the consequences of increased glycated albu-
min in diabetes on mesangial cell biology are similar in vivo,
abrogating its influence by lowering plasma glycated albumin
and/or neutralizing its biologic activity could have a salutary
influence on the development of glomerular pathology in dia-
betic animals. The availability of monoclonal antibodies that
specifically react with Amadori glucose adducts in albumin, and
which prevent the in vitro effects of glycated albumin on
mesangial cell biology, provided the opportunity to explore this
possibility [20, 21, 27]. We report that parenteral administration
of these antibodies to db/db mice, a genetic model of diabetes in
which mesangial changes resembling those found in human
diabetes are observed [28, 29], has a salutary influence on the
development of diabetic nephropathy in this animal model.
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Methods
Experimental animals
Diabetic db/db mice and their nondiabetic db/m littermates
were purchased from Jackson Research laboratories. The db/db
mice were designated as diabetic by the vendor on the basis of
appearance of obesity at about five weeks of age. One-hall of
the db/db and db/m mice received intraperitoneal injections of
100 g of the A717 monoclonal antibody (FAb fragments) in
buffered saline weekly for seven weeks, commencing between
seven to nine weeks of age. Non-injected db/db and db/m mice
served as controls. The mice were housed in individual meta-
bolic cages and provided food and water ad libitum. Twenty-
four hour urine samples were collected at the beginning, two
weeks after the start of the study, and at the conclusion of the
study for measurement of albumin excretion. Blood glucose
was determined weekly on whole blood samples obtained by
orbital puncture. Blood samples also were obtained to measure
plasma glycated albumin concentrations at various intervals.
Animals were sampled twice for these measurements, before
antibody injection and seven days after the preceding antibody
injection. The antibody-treated db/db mice were sampled once
additionally, within 48 hours of antibody administration. Our
reasoning was that, since albumin has a half-life of about three
days in the mouse (see below), glycated albumin would be at
pre-injection levels by seven days after antibody and that an
effect of antibody on plasma glycated albumin would most
likely be detectable within 48 hours after antibody injection.
Animals were killed at the conclusion of the study, and the renal
cortex was examined by light microscopy after staining with
hematoxylin and eosin.
Antibody preparations, reactivity and administration
Monoclonal antibody was harvested from ascitic fluid of mice
injected intraperitoneally with 1 x i0 cells of the A7l7 clone,
and purified by affinity chromatography on protein G. FAb
fragments were prepared with papain digestion, using papain
immobilized onto 6% beaded agarose (Pierce, Rockford, Illi-
nois, USA) equilibrated with digestion buffer. The purified
antibody in digestion buffer was incubated for five hours at 37°C
in a shaking water bath; the digest was separated from the
immobilized papain, which was washed with binding buffer and
the wash was added to the digest. FAb fragments in the digest
were then separated from Fc fragments and undigested IgG
with protein A affinity chromatography. The FAb preparations
were tested in enzyme-linked immunosorbent assay (ELISA) to
ensure retention of combining ability with the glycated albumin
epitope [131. In this assay, glycated albumin was immobilized
onto microtiter wells and incubated with the monoclonal
antibody preparation, followed by incubation with enzyme-
conjugated polyclonal antibody against mouse FAb and then
substrate. The A717 FAb fragments yielded a dose response
relationship with increasing concentrations of glycated albumin
when detected with the anti-mouse FAb conjugate. No reactiv-
ity was observed when conjugated anti-mouse Fc was used as
detector. Removal of Fc fragments and undigested antibody in
the preparations was documented by ELISA wherein the FAb
antibody fragments reacted with enzyme conjugated anti-mouse
FAb, but not with enzyme conjugated anti-mouse Fc.
A7l7 is a murine monoclonal antibody of the IgG1 class that
selectively recognizes Amadori epitopes in glycated albumin,
does not react with AGE modified albumin, and does not react
with other serum proteins, whether glycated or not [13, 20, 21,
27]. Since the immunogen for A717 was glycated albumin
purified from human plasma, we established reactivity of the
antibodies with the epitope in the murine protein by a compet-
itive ELISA in which glycated mouse albumin in soluble phase
competed with glycated human albumin immobilized onto mi-
crotiter wells for binding to enzyme-conjugated A717 (see
below). We have previously shown in direct ELISA that the
A7l7 monoclonal antibody reacts with glycated rat albumin,
detecting the epitope bound in primary incubation to monoclo-
nal antibody immobilized onto microtiter wells by secondary
incubation with enzyme-conjugated polyclonal antibody against
the rodent albumin [30]. The principal requirement for epitopic
recognition by A7l7 appears to be the fructosyl-lysine adduct in
lys-lys or lys-his sequence carried within a domain specific to
albumin. Albumin is a highly conserved molecule, and the
glycatable residues of rodent albumin have sequence homology
with human albumin. In particular, the lysine 525 residue,
which is the predominant site undergoing glycation in vivo [31,
32], is contained within identical sequences in rodent and
human albumin [33, 34]; namely, gln-ile-lys-lys-gln-thr-ala-leu.
Thus, the A717 recognizes an analogous epitope in human and
rodent glycated albumin.
For injection, the FAb preparations were sterile filtered and
administered in sterile buffered saline. Antibody treated db/db
and db/m mice received 100 g of FAb fragments weekly for
seven weeks by intraperitoneal injection, commencing between
seven to nine weeks of age.
Analytical procedures
Albumin excretion was measured by a competitive ELISA in
which mouse albumin in soluble phase competed with albumin
immobilized onto microtiter wells (250 ng/well) for binding to
horseradish peroxidase (HRP)-conjugated antibody against ro-
dent albumin. After addition of sample or standard in 200 1d
reaction buffer and equilibration for 60 minutes, HRP-conjugate
(1:4000 dilution in 10% fetal call serum, 0.1 M Tris, pH 6.8) was
added and the reaction allowed to proceed for 30 minutes at
room temperature. After washing with saline containing Tween
20, substrate color developer (TMBlue) and then stopper (1 M
H2S04) were added, and the absorbances in the wells were read
at 450 nm in an ELISA reader. Color intensity is inversely
proportional to the amount of albumin. The assay is sensitive to
0.1 and shows linearity with the log of concentrations
between 10 to 1000 g/ml. Urine creatinine was measured with
the creatinine color reagent (Sigma Chemical Co., St. Louis,
Missouri, USA).
Plasma concentrations of glycated albumin were measured by
competitive enzyme immunoassay. Microtiter wells were pre-
coated with albumin containing a mixture of glycated and
nonglycated species and were incubated with standard (gly-
cated albumin) or plasma sample and HRP-conjugated A717
(1:2000), both diluted in reaction buffer (0.01 M EDTA, 0.15 M
NaCI, 0.001% casein, pH 6.8), followed by development with
TMBlue substrate. The assay was sensitive to 1 g and showed
an inverse dose response relationship between 2 to 200 pg
glycated albumin.
Cohen et al: Monoclonal antibody treatment in diabetic nephropathy 1675
Week of study
2 4 6 7
Body wt g
db/m (NI) 24.5 0.2 26.7 0.4 25.3 0.6 27.6 0.9
db/m (I) 24.7 0.4 25.3 0.6 27.2 0.8 29.3 0.8
Mean 24.6 0.3 26.0 0.5 26.3 0,7 28.5 0.8
db/db (NI) 39.1 0.8 37.8 1.2 39.1 1.9 39.3 2.7
db/db (I) 34.8 2.0 33.1 2.6 34.8 3.0 36.8 2.5
Mean 37.0 1.4 35.5 1.9 37.0 1.9 38.0 2.6
Glucose mM
db/m (NI) 4.7 0.7 3.9 0.9 3.7 0.4 5.6 0.7
db/m (I) 5.7 0.8 7.0 0.7 6.5 1.6 6.9 0.7
Mean 5.2 0.7 5.5 0.8 5.1 1.0 6.3 0.7
db/db (NI) 20.6 4.7 22.5 3.7 17.8 2.2 21.6 4.3
db/db (I) 23.6 4.4 21.1 4.0 17.8 2.3 21.5 4.6
Mean 22.1 4.6 21.8 3.8 17.8 2.2 21.6 4.5
Results
The db/db mouse is a genetic model that develops hypergly-
cemia associated with obesity a few weeks after birth, and
subsequently enters an insulin deficient phase with weight loss
and premature death when left untreated. At the start of this
study, all diabetic animals exhibited hyperglycemia, which
persisted throughout the experimental period; nondiabetic mice
remained normoglycemic during the study period (Table 1).
Mean blood glucose concentrations in the two groups of db/m
mice were significantly different at weeks 4 and 6 of the study,
but values were within the normal range for rodents (Table 1).
Mean body weight in db/db mice was greater than in db/m mice
at the beginning and the end of the study (Table 1), although
some individual db/db mice weighed less at the conclusion than
at the start of the study. A significant difference between mean
body weights in the two groups of db/db mice at week 2 of the
study is without apparent explanation, other than biologic
variability, and mean body weights of antibody-treated db/db
mice showed some fluctuation during the study. The db/m mice
gained weight during the study period (Table 1).
The antibody injection schedule was arbitrarily selected on
the basis of certain assumptions regarding the estimated amount
of glycated albumin to be neutralized, the half-life of albumin,
stoichiometric relationships, published studies using multiple
injections of monoclonal antibodies, and the ability of the
antigen-antibody interaction to enhance removal of glycated
albumin from the circulation [35—42]. We estimated mouse
plasma volume at 1.2 ml, with an albumin concentration of
15 mg/mi, of which 1 to 3% might be glycated. This would
correspond with an approximate total plasma glycated albumin
between 180 and 540 g. We further estimated that total plasma
glycated albumin would be one and a half to two times greater
in diabetic than in nondiabetic mice, and that a desirable
antibody dose would lower glycated albumin concentrations in
diabetic animals to nondiabetic levels. This would require about
50 g of antibody FAb fragments for each tmol glycated
albumin to be neutralized. Albumin has a circulating half-life of
three days in the mouse, although glycation may slow clearance
db/m db/m db/db db/db db/db
NI I NI I I—48hr
Fig. 1. Plasma glycated albumin concentrations in db/m and db/db
mice. Samples were obtained twice during the study period from
animals in each experimental group. Blood was obtained by orbital
puncture immediately before antibody injection, seven days after the
preceding injection, in the animals treated with monoclonal antibody.
Abbreviations are: NI, non-injected; I, antibody injected. In the indi-
cated antibody-treated db/db mice (1-48), blood was obtained within 48
hours after the preceding antibody injection. Values are mean + SEM of
8 measurements each group, except 1-48, which represents mean + SEM
of 4 measurements. *P < 0.05 compared with db/m and with the 1-48 hr
db/db values.
of plasma proteins [36, 37, 40—42], prompting the weekly
injection schedule. Measurement of plasma glycated albumin
concentrations supported our assumptions and approach. Gly-
cated albumin was significantly increased in plasma from db/db
compared with db/m mice, and was reduced when measured
within 48 hours after antibody injection (Fig. 1).
A beneficial effect of treatment with the anti-glycated albumin
monoclonal antibody on renal function was sought by measur-
ing albumin excretion, the established parameter reflecting
diabetic renal glomerular dysfunction [43]. Urine albumin con-
centrations, normalized in relation to creatinine concentration
to control for possible incomplete collection, were significantly
increased in db/db compared with db/m mice at the start of the
study (pre-injection). Albumin excretion remained elevated and
significantly greater in the noninjected db/db controls compared
with db/m controls during the ensuing weeks (Fig. 2). However,
at the conclusion of the study period, albumin excretion was
significantly reduced in antibody treated db/db mice compared
with the untreated db/db controls (Fig. 2). Albumin excretion in
nondiabetic db/m mice was unchanged by monoclonal antibody
treatment (Fig. 2).
Histologic examination of glomeruli in renal sections ob-
tained when animals were killed after the seventh study week
revealed mesangial prominence, with increased mesangial ma-
trix encroaching the normal capillary network in untreated
db/db mice (Fig. 3 C, D). In contrast, glomeruli from antibody-
treated db/db mice did not exhibit mesangial matrix accumula-
tion (Fig. 3 E, F), and most specimens did not appear different
Table 1. Body weights and blood glucose concentrations in db/m and
db/db mice that were not injected (NI) or received weekly
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Discussion
The lesion of diabetic nephropathy, which is characterized by
mesangial matrix accumulation in association with glomerular
hypertrophy, decreased cellularity, and a thickened glomerular
basement membrane, is believed to originate in the glomerular
mesangium [22—25]. Mesangial cells synthesize Type IV colla-
gen, the predominant constituent of the expanded mesangial
matrix and, in culture, exhibit biosynthetic and proliferative
responses to media manipulations that have helped provide
insight into potential nephropathic factors. For example, ele-
vated concentrations of glucose in the culture media have been
shown to influence mesangial cell proliferation or collagen
synthesis [44—46]. We have reported that glycated albumin
inhibits the proliferation of mesangial cells in culture and
stimulates Type IV collagen production and gene transcription
[20, 21]. These effects on mesangial cell biology were initially
demonstrated with serum containing concentrations of the
Amadon product of the glycation reaction approximating those
found in diabetic serum, and were confirmed with glycated
albumin that was purified to a homogeneous band of approxi-
mately 66 kDa, was devoid of AGE-fluorescence or crosslinks,
represented the physiologic construct, and was added to cul-
tures in concentrations encompassing those found in diabetic
subjects. The glycated albumin-induced effects on collagen
production and cell proliferation were prevented when A717
monoclonal antibodies were added to the cell cultures. A717
had no effect on cells cultured with nonglycated albumin, and
IgG not reactive with glycated albumin did not influence colla-
gen production or cell proliferation when added to cultures
supplemented with either glycated or nonglycated albumin. We
interpreted these results as highly relevant to the pathogenesis
of diabetic nephropathy, although we noted that caution must
be exercised in extrapolating in vitro findings with cells in
culture to the in vivo situation. Nevertheless, the ability of the
A717 monoclonal antibodies to prevent the observed in vitro
effects of glycated albumin on mesangial cell biology suggested
that treatment with these antibodies might prove beneficial in
slowing the development of nephropathic lesions in vivo. This
hypothesis was examined in the present experiments, which
demonstrate that reducing glycated albumin concentrations
and/or blocking its biologically-active glycated epitopes has a
salutary influence on glomerular structural and functional
changes reflecting nephropathic involvement in the db/db
mouse. Notably, we did not treat the db/db mice with insulin or
other glucose-lowering agent, and blood glucose concentrations
at the conclusion of the study remained as elevated as they were
at the initiation of the study period. Thus, treatment with the
monoclonal antibodies had a beneficial influence independent of
any effect on glycemic status.
Glucose-derived modifications of proteins can alter structural















Fig. 2. Albumin excretion in db/m and db/db
mice, untreated (-) or receiving weekly
intraperitoneal injections of 100 ,sg of A717
monoclonal antibody FAb fragments (+).
Fouranimals in each experimental group.
Results are expressed as mg albumin/mg
creatinine and represent mean + SEM. *D <
0.05 compared with untreated db/db controls.
3 A, B). Glomeruli from
not appear different from
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Fig. 3. Effect of A717 antibody to glycated albumin on glomerular histology in db/db mice. Sections stained with hematoxylin and eosin. A and
B, normal control (db/m); C and D, diabetic (db/db) control. An appreciable increase in mesangial matrix is seen as amorphous material within the
glomerulus; E and F, diabetic (db/db) treated with weekly injections of A717 monoclonal antibody. An effect of anti-glycated albumin monoclonal
antibody treatment is observed in preventing the increased mesangial matrix that is illustrated in C and D.
and functional properties, and early and late products of the
glycation reaction both have been implicated in the pathogen-
esis of diabetic complications [10, 14, 20, 21, 47—501. Recent
focus on possible AGE-induced pathophysiology has shifted
attention from the potential role of Amadori glycation products
in the development of chronic complications of diabetes such as
nephropathy. However, formation of AGE can only occur
subsequent to glycation, and some investigators have regarded
-L
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AGE rearrangement as a "fixative" of the glycation of proteins,
marking the occurrence of glycation-induced deleterious events
for which formation of the glucose adduct may be the critical
event [51]. The mechanism by which glycated albumin induces
pathobiologic events in the renal glomerulus is currently un-
known, but may relate to binding to membrane-associated
polypeptides [52—54] thatcould trigger receptor-induced events.
Although additional studies are necessary to define these
events, our results nevertheless provide direct evidence for a
causal role of Amadori-modified glycated albumin in the patho-
genesis of diabetic nephropathy, and suggest a new approach
for arresting the development or progression of this morbid
complication of diabetes.
Reprint requests to Margo P. Cohen, M.D., 3508 Market Street,
Suite 420, Philadelphia, Pennsylvania 19104, USA.
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